

cost of symptomatic drugs (−22% for R; −34% for R + A) in SLIT patients. **CONCLUSIONS:** Use of symptomatic drugs is an important indicator of effective allergy control: other studies have shown SLIT can reduce the use of drugs for asthma and rhinitis, but this is the first time this outcome is demonstrated in a routine care population, in the medical practice environment of an observational study, and yet at the first year of treatment.

PAA3

COST OF MANAGING ASTHMA EXACERBATIONS WITH STABLE DOSING OF SALMETEROL/FLUTICASONE COMBINED PRODUCT (SFC) COMPARED WITH ADJUSTABLE MAINTENANCE DOSING (AMD) OF FORMOTEROL/BUDESONIDE COMBINED PRODUCT (FBC) IN POLAND

Orlewska E¹, Cel M², Glogowski C²

¹Centrum Farmakoekonomiki, Warsaw, Poland, ²GSK Commercial Sp. z o.o., Warsaw, Poland

OBJECTIVES: Exacerbations—consequence of poor control of asthma—are the main component of high cost of this disease. The aim of the study was the cost comparison of managing asthma exacerbations with two types of treatment: stable dosing of SFC and AMD of FBC. **METHOD:** The analysis was performed from health-care payer perspective, based on Polish data on health-care resource utilisation and unit cost obtained from COAX study, estimating cost of asthma exacerbation managed in primary and secondary care in Poland. Data on incidence of asthma exacerbations in two types of treatment were derived from 1-year CONCEPT Trial—the only available double blind, double dummy, randomized study in adults with persistent asthma, comparing stable dosing SFC with AMD of FBC. **RESULTS:** Study population was 688 patients (344 in each treatment arm). 11.3% patients on stable dosing of SFC experienced an asthma exacerbation compared with 17.7% patients receiving AMD of FBC. There were 48% fewer exacerbations in the stable dosing SFC group than in AMD with FBC (50 vs. 96 exacerbations respectively). The incidence of asthma exacerbations requiring oral steroids or an emergency room visit/hospitalization was 47% lower for the stable dosing SFC group than for AMD with FBC (adjusted annual mean rate, 0.18 vs 0.33; $P = 0.008$). The total annual direct health care costs of managing exacerbations for the stable dosing SFC group was PLN 19.833 compared with PLN 34.936 for the AMD with FBC group. Difference in annual costs of managing exacerbations was PLN 15.103 (EUR 1 = PLN 4,02; year 2005). **CONCLUSION:** Stable dose treatment with salmeterol/fluticasone combined product of adult patients with persistent asthma is more effective than the adjustable maintenance dosing with formoterol/budesonide combined product and reduces the cost of exacerbations management by 43%.

PAA4

PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA PATIENTS

Kulikov A, Lomakin A, Krysanov I, Polivanov V

Moscow Medical Academy, Moscow, Russia

OBJECTIVES: To perform cost-effectiveness analysis of combos budesonide/formoterol in different dosing regimes and fixed dosing salmeterol/fluticasone in bronchial asthma (BA) treatment in Russia. **METHODS:** Modeling study based on the results of international randomized double blind study of 6 countries outpatient practice published by R. Albers, et al.* Three

group patients with BA were assessed: group 1 ($n = 219$)—adjustable maintenance dosing budesonide/formoterol 160/4,5 micrograms, 1st month—2 inhalations twice a day and next 6 month—on average 3,4 inhalations a day; group 2 ($n = 215$)—fixed dosing the same product, 2 inhalations twice a day and group 3 ($n = 224$)—fixed dosing salmeterol/fluticasone 50/250 micrograms, 1 inhalation twice a day. Direct medical costs (DC) were taken into account from the health care system point of view and consisted of expenditures on products usage and treatment of complications. Effectiveness (E) was the average percent of pts with a week of well-controlled asthma based on clinical study results. There was a significant positive dynamics in all groups accordingly: E1 = 65%, E2 = 50% and E3 = 55%. **RESULTS:** Direct cost (DC) for each group were: DC1 = 364 EUR, DC2 = 417 EUR and DC3 = 420 EUR respectively. Cost—effectiveness ratio (CER): CER1 = 5.58, CER2 = 8.34 and CER3 = 7.63 EUR per percent of pts with a week of well-controlled asthma respectively as well. **CONCLUSION:** adjustable maintenance dosing budesonide/formoterol is the best choose to treat pts with BA based on cost-effectiveness analysis results.

*-R. Albers, et al. Current medical research and opinion. 2004;20:225–40.

PAA5

ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN GERMANY

Berg J¹, Lindgren P¹, Jönsson B²

¹Stockholm Health Economics, Stockholm, Sweden, ²Stockholm School of Economics, Stockholm, Sweden

OBJECTIVES: Fractional exhaled nitric oxide (FENO) is a measure for the airway inflammation underlying asthma, which can be used for both diagnosis and monitoring the effect of anti-inflammatory treatment. The objective of this study was to assess the cost-effectiveness of NIOX MINO®, a portable non-invasive FENO monitor, in asthma diagnosis and management. **METHODS:** Two decision trees were constructed that capture the different alternatives and consequences in asthma diagnosis and management. Reflecting available clinical data on diagnostic precision, NIOX MINO was compared against standard diagnostics, including spirometry, reversibility testing, bronchoprovocation and sputum eosinophil count. The impact of asthma management with NIOX MINO on inhaled steroid use, exacerbations and hospitalisations was compared against standard guidelines (spirometry) over a 1-year timeframe. A German payer perspective was chosen, focusing on direct medical costs taken from published sources in 2006. Effectiveness was measured in quality-adjusted life-years (QALYs). **RESULTS:** Asthma diagnosis based on NIOX MINO results in a cost of €12 per patient, including the cost of false diagnoses, compared to €20 for standard diagnostics. If NIOX MINO is conducted in addition to standard tests, the incremental cost would be up to €7 per patient. Asthma management with NIOX MINO instead of standard guidelines is a dominant strategy. In mild to severe patients, it results in cost-savings of €140 per patient and year and 0.06 QALYs gained. In a more severe population, management with NIOX MINO would save costs of €260 per patient and lead to 0.004 QALYs gained. **CONCLUSIONS:** Asthma diagnosis based on NIOX MINO alone is less costly and more accurate than standard diagnostic methods, while the addition of NIOX MINO to spirometry increases costs marginally. The use of NIOX MINO in treatment decisions is less costly than asthma management based on standard guidelines, while providing the same health benefits.